Metropolis Healthcare IPO GMP History
Metropolis Healthcare IPO has been listed on April 15, 2019 at a listing price of ₹958, against the issue price of ₹880 — a gain of ₹78 (+8.86%). The GMP peaked at ₹97.5 on 2 April 2019 and reached a low of ₹17.5 on 7 April 2019. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Metropolis Healthcare IPO raised ₹1204.29 Cr. through its IPO at a price band of ₹877 to ₹880 per share, with a lot size of 17 shares. The IPO was open for subscription from 03 Apr 2019 to 05 Apr 2019.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 12 Nov, 3:12 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 14 Apr 2019 | ₹ 47.5 | — | 5% | — | — |
| 13 Apr 2019 | ₹ 47.5 | ▲ | 5% | — | — |
| 12 Apr 2019 | ₹ 32.5 | — | 4% | — | — |
| 11 Apr 2019 | ₹ 32.5 | — | 4% | — | — |
| 10 Apr 2019 | ₹ 32.5 | — | 4% | — | — |
| 09 Apr 2019 | ₹ 32.5 | ▼ | 4% | — | — |
| 08 Apr 2019 | ₹ 52.5 | ▲ | 6% | — | — |
| 07 Apr 2019 | ₹ 17.5 | — | 2% | — | — |
| 06 Apr 2019 | ₹ 17.5 | — | 2% | — | — |
| 05 Apr 2019 | ₹ 17.5 | ▼ | 2% | — | — |
| 04 Apr 2019 | ₹ 55 | ▼ | 6% | — | — |
| 03 Apr 2019 | ₹ 85 | ▼ | 10% | — | — |
| 02 Apr 2019 | ₹ 97.5 | — | 11% | — | — |
| 01 Apr 2019 | ₹ 97.5 | — | 11% | — | — |
| 31 Mar 2019 | ₹ 97.5 | ▲ | 11% | — | — |
| 30 Mar 2019 | ₹ 47.5 | — | 5% | — | — |
| 29 Mar 2019 | ₹ 47.5 | — | 5% | — | — |
| 28 Mar 2019 | ₹ 47.5 | — | 5% | — | — |
| 27 Mar 2019 | ₹ 47.5 | — | 5% | — | — |
Metropolis Healthcare IPO dates
Key dates from opening to listing. Today is 14 November.
- Open 03 Apr 2019
- Close 05 Apr 2019
- Allotment 10 Apr 2019
- Refund/credit 11 Apr 2019
- Listing 15 Apr 2019
Metropolis Healthcare IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹880 |
|---|---|
| GMP-based estimate (pre-listing) | ₹927 (+5.3%) |
| Listing gain / loss | +₹78 per share |
| Listing date | 15 Apr, 2019 |
| Actual listing price | ₹958 (+8.86%) |
Is Metropolis Healthcare IPO GMP reliable?
Grey market premium for Metropolis Healthcare IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Metropolis Healthcare IPO full review for a fundamentals-based assessment before making any grey market trades.
Metropolis Healthcare IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Metropolis Healthcare IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Metropolis Healthcare IPO
Metropolis Healthcare Limited is a Mumbai based chain of diagnostic laboratories. Its promoters are Sushil Kanubhai Shah, Ameera Sushil Shah and Metz Advisory.
It had 106 clinical laboratories and 1130 collection centres across seven countries.
In India its labs cover 18 states and 173 cities, for disease monitoring, early detection and screening, and it also supports clinical research.
The IPO was Rs 1,204.29 crore and was entirely an offer for sale at Rs 880, the top of the Rs 877 to Rs 880 band, so the company received no money.
Frequently asked
What is the GMP of Metropolis Healthcare IPO?
The current Grey Market Premium (GMP) of Metropolis Healthcare IPO is ₹ 47.5.
What is the Kostak Price of Metropolis Healthcare IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Metropolis Healthcare IPO is not available.
What is the Subject to Sauda Price of Metropolis Healthcare IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Metropolis Healthcare IPO?
Metropolis Healthcare IPO listed on April 15, 2019 at ₹958, against the issue price of ₹880 — a gain of +8.86%.
How did the GMP of Metropolis Healthcare IPO trend before listing?
The GMP of Metropolis Healthcare IPO was stable in its final days before listing. The GMP peaked at ₹97.5 on 2 April 2019. View the day-wise table above for the complete GMP history.
Explore Metropolis Healthcare IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
